Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
This product is currently not marketed in the UK. In the absence of a submission from the holder of the marketing authorisation, sirolimus (Rapamune®) cannot be endorsed for use within NHS Wales for the treatment of patients with sporadic lymphangioleiomyomatosis with moderate lung disease or declining lung function |
||
|
||
Medicine details |
||
| Medicine name | sirolimus (Rapamune®) | |
| Formulation | 1 mg/ml oral solution, 0.5 mg tablet, 1 mg tablet, 2 mg tablet | |
| Reference number | 2707 | |
| Indication | For the treatment of patients with sporadic lymphangioleiomyomatosis with moderate lung disease or declining lung function |
|
| Company | Pfizer Ltd | |
| BNF chapter | Respiratory system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 03/12/2018 | |
| Date of issue | 04/12/2018 | |